These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Nanomedicine and drug delivery. Wei C; Wei W; Morris M; Kondo E; Gorbounov M; Tomalia DA Med Clin North Am; 2007 Sep; 91(5):863-70. PubMed ID: 17826106 [TBL] [Abstract][Full Text] [Related]
4. Nanomedicine: the promise and challenges in cancer chemotherapy. Naguib YW; Cui Z Adv Exp Med Biol; 2014; 811():207-33. PubMed ID: 24683034 [No Abstract] [Full Text] [Related]
5. Nanomedicine in cancer treatment. Yih TC; Wei C Nanomedicine; 2005 Jun; 1(2):191-2. PubMed ID: 17292078 [No Abstract] [Full Text] [Related]
6. Cancer nanomedicine: from targeted delivery to combination therapy. Xu X; Ho W; Zhang X; Bertrand N; Farokhzad O Trends Mol Med; 2015 Apr; 21(4):223-32. PubMed ID: 25656384 [TBL] [Abstract][Full Text] [Related]
7. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Pridgen EM; Langer R; Farokhzad OC Nanomedicine (Lond); 2007 Oct; 2(5):669-80. PubMed ID: 17976029 [TBL] [Abstract][Full Text] [Related]
8. Programmable nanomedicine: synergistic and sequential drug delivery systems. Pacardo DB; Ligler FS; Gu Z Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684 [TBL] [Abstract][Full Text] [Related]
10. Surface-active liposomes for targeted cancer therapy. Sofou S Nanomedicine (Lond); 2007 Oct; 2(5):711-24. PubMed ID: 17976032 [TBL] [Abstract][Full Text] [Related]
11. Peptide chemistry encounters nanomedicine: recent applications and upcoming scenarios in cancer. Falanga A; Galdiero S Future Med Chem; 2018 Aug; 10(16):1877-1880. PubMed ID: 29921135 [No Abstract] [Full Text] [Related]
12. Anticancer drug delivery with nanoparticles. Conti M; Tazzari V; Baccini C; Pertici G; Serino LP; De Giorgi U In Vivo; 2006; 20(6A):697-701. PubMed ID: 17203748 [TBL] [Abstract][Full Text] [Related]
13. Nanoscale drug delivery for targeted chemotherapy. Xin Y; Huang Q; Tang JQ; Hou XY; Zhang P; Zhang LZ; Jiang G Cancer Lett; 2016 Aug; 379(1):24-31. PubMed ID: 27235607 [TBL] [Abstract][Full Text] [Related]
14. Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery. Sun D; Chen J; Wang Y; Ji H; Peng R; Jin L; Wu W Theranostics; 2019; 9(23):6885-6900. PubMed ID: 31660075 [TBL] [Abstract][Full Text] [Related]
15. Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy. Krishnan V; Rajasekaran AK Clin Pharmacol Ther; 2014 Feb; 95(2):168-78. PubMed ID: 24013811 [TBL] [Abstract][Full Text] [Related]
17. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives. Cadete A; Alonso MJ Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874 [TBL] [Abstract][Full Text] [Related]
18. A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis. Lim EH; Danthi N; Bednarski M; Li KC Nanomedicine; 2005 Jun; 1(2):110-4. PubMed ID: 17292065 [No Abstract] [Full Text] [Related]
19. Nanomedicine: sizing up targets with nanoparticles. Minchin R Nat Nanotechnol; 2008 Jan; 3(1):12-3. PubMed ID: 18654442 [No Abstract] [Full Text] [Related]
20. Engineering the nanoparticle-protein interface for cancer therapeutics. Saie AA; Ray M; Mahmoudi M; Rotello VM Cancer Treat Res; 2015; 166():245-73. PubMed ID: 25895872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]